Cystatin C (Cys-C), an alternative to renal markers like creatinine and glomerular filtration rate, can effectively predict a patient’s risk for adverse CVD events after an acute coronary syndrome (ACS), researchers reported Oct. 12 in the Journal of the American Heart Association.